The 2001 serological survey in the Czech Republic--rubella.
In total, 3,009 sera from a representative population sample of the Czech Republic, 1508 females and 1,501 males, were tested by EIA using a commercial kit ETI-RUBEK-G Plus manufactured by Dia Sorin, Italy. The vaccination strategy was as follows: vaccination of 12-year-old girls since 1982 and all 2-year-olds vaccinated since 1986. Currently, all women under 31 years of age and all men under 17 years of age have been vaccinated. The results of the serological survey confirmed lower seropositivity rates in young men compared to vaccinated women of the same age as expected. An epidemic outbreak of rubeola among young men is another evidence of that The seropositivity rate of 2- 9-year-old vaccinee children reaches almost 95%. The long-term morbidity trend in the Czech Republic is downward sloping, with a marked differentiation between the male and female populations.
Mrázová
M
M
Centre of Epidemiology and Microbiology, NRL for mumps, measles and rubella, National Institute of Public Health, Prague, Czech Republic.
Smelhausová
M
M
Sestáková
Z
Z
Svandová
E
E
Benes
C
C
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D018153:Czech Republic / Q000453:epidemiology; D003625:Data Collection; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D012409:Rubella / Q000097:blood / Q000453:epidemiology* / Q000276:immunology; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000276:immunology; D012412:Rubella virus / Q000276:immunology; D012698:Serologic Tests
D000914:Antibodies, Viral; D012411:Rubella Vaccine